What's Happening?
Wearable devices are increasingly being incorporated into clinical trials, often as part of broader digital product strategies rather than being fully integrated into the core clinical development strategy. This approach can lead to several issues, including
the treatment of wearable data collection as optional, a lack of operational rigor, and insufficient attention to adherence compared to established clinical endpoints. Digital health teams, which often operate separately from clinical development teams, may struggle to demonstrate the clinical relevance of their solutions. This disconnect means that while wearables offer significant opportunities to extend the impact of therapeutic interventions, their full potential in generating robust longitudinal evidence for clinical decision-making is not being realized. The current dynamic often results in wearable-derived measurements being relegated to exploratory or supportive roles, rather than becoming primary or key secondary endpoints.
Why It's Important?
The current challenges in integrating wearables into clinical trials have significant implications for the U.S. healthcare and pharmaceutical industries. A lack of standardization in wearable-derived measurements, including common operational definitions, data representations, and transparent processing pipelines, hinders the ability to compare evidence across clinical programs and build a sustainable clinical evidence base. This can delay the development and approval of new treatments, as regulatory bodies require rigorous validation of endpoints. Furthermore, the reliance on proprietary algorithms and device-specific characteristics means that changing a wearable device can necessitate restarting substantial validation processes, increasing costs and timelines for clinical trials. For patients, this means a slower adoption of potentially beneficial digital health solutions that could offer more personalized and continuous monitoring of their health and treatment responses.
What's Next?
To overcome these challenges, there is a critical need for digital health expertise to be integrated into clinical development from the earliest stages, with a clear understanding of the intended context of use, endpoint strategy, and evidence-generation requirements. The focus needs to shift from validating individual devices and proprietary outputs to establishing reproducible, interpretable, and technology-independent measurements supported by transparent methodological standards. This will require collaboration among pharmaceutical companies, technology developers, and regulatory bodies to develop industry-wide standards and best practices. Future efforts will likely involve defining what constitutes 'raw' sensor data and ensuring that measurements are consistently defined across different technologies to enable meaningful comparisons and robust evidence generation. Without these foundational changes, the contribution of wearables to clinical decision-making may remain largely exploratory.
Beyond the Headlines
The issues surrounding wearables in clinical trials extend beyond mere technical hurdles, touching upon fundamental questions of scientific rigor and ethical considerations in data collection. The current fragmented approach raises concerns about data quality and the potential for bias if data collection is treated as optional or lacks consistent operational rigor. There's also an ethical dimension to how patient data from wearables is collected, processed, and used, especially when these devices are part of broader digital product strategies that may have commercial interests beyond the clinical trial itself. The lack of clear definitions for what wearable devices are measuring—whether it's behavior, physiological processes, or 'digital biomarkers'—highlights a deeper conceptual challenge that needs to be addressed to ensure the scientific validity and trustworthiness of these new data streams. Ultimately, the successful integration of wearables requires a re-evaluation of how digital health is perceived and incorporated into the scientific and regulatory frameworks of clinical research.
